We Work for Health | WA

We Work For Health Washington is a grassroots coalition showcasing the tremendous impact the life sciences industry brings to the state of Washington.

[We Work for Health | WA @WWFH_WA]

"MFN would move the United States in exactly the wrong direction. Rather than forcing foreign governments to contribute more to innovation, MFN would effectively import their price controls by pegging U.S. drug prices to the lowest prices abroad."

https://t.co/aeeEJ5kkvN

[We Work for Health | WA @WWFH_WA]

Tune in to the Making Medicine Podcast to hear federal leaders speak to:
🔹 The “pill penalty” and the EPIC Act
🔹 How the IRA changed biotech investment incentives
🔹 China’s growing role in global biotech
🔹 The importance of bipartisan problem-solving

https://t.co/zEgbZd7rvi

[We Work for Health | WA @WWFH_WA]

"Europe believes it has a right to American taxpayer generosity. For too long, they have underinvested in their own defense while expecting Washington to foot the bill."

#MFN puts the U.S. at a competitive disadvantage: https://t.co/s6h6LAEKTq

[We Work for Health | WA @WWFH_WA]

"Half of all new medicines are developed in the United States, yet Americans pay two to three times more for those medicines than people in other developed countries.

If it sounds unfair, that’s because it is."

#MFN disincentivizes R&D: https://t.co/UBoovee7Cu

[We Work for Health | WA @WWFH_WA]

Curious about the impact of #340B on your employer-sponsored health plan?

Calculate the cost in Washington state here: https://t.co/MLPWU7YxhD

[We Work for Health | WA @WWFH_WA]

Tune in for a discussion on MFN policy and efforts to reduce U.S. drug prices by linking them to prices in other high-income countries, all while maintaining overall industry revenues through higher prices abroad: https://t.co/K6Owu7lNQ5

[We Work for Health | WA @WWFH_WA]

"Price controls hurt German patients by restricting the availability of new drugs. German patients only had access to about 60% of medicines launched globally between 2014 and 2021.

American patients could access 85% of those medicines."

#MFN in action: https://t.co/IN54ujdngD

[We Work for Health | WA @WWFH_WA]

"Drugmakers disproportionately rely on revenue from the United States to sustain research and development. While patients abroad often pay cut-rate prices, Americans pay far more for the same meds."

#MFN isn't a good deal for the U.S.: https://t.co/3TNnDt6Bpm

[We Work for Health | WA @WWFH_WA]

#ICYMI: China’s rapidly growing Phase 1 and 2 pipeline is closing the gap with the U.S., creating global competition in the race to develop the next generation of therapies.

More from @dcexaminer: https://t.co/uVzOF12XmD

[We Work for Health | WA @WWFH_WA]

"Nearly all of America's trading partners use a variety of price controls and non-tariff trade barriers, such as deliberate bureaucratic delays and not-so-subtle threats to invalidate American companies' patent protections."

https://t.co/6uSVlj1MQO

[We Work for Health | WA @WWFH_WA]

"It takes roughly $2.7 billion, on average, to successfully bring a drug to market. It’s also risky, as roughly 90% of drugs that enter clinical trials never make it to patients."

#MFN won't bolster the innovation economy: https://t.co/MGTiDZY2M7

[We Work for Health | WA @WWFH_WA]

"#340B spending has ballooned as more hospitals have become eligible owing to the ObamaCare Medicaid expansion. Now some of the wealthiest hospitals in the U.S. qualify, and there is no requirement that they use the discounts to directly help patients."

https://t.co/7qxfRnYPMh

[We Work for Health | WA @WWFH_WA]

What does high-value, affordable healthcare actually look like? How do we get there?

WWFH is sponsoring Beyond the Bottom Line on May 13 in Seattle: We believe the answers start with employers, providers, and health plans working together.

Register: https://t.co/9Ggl8qhkX7

[We Work for Health | WA @WWFH_WA]

"If MFN pricing undermines the investment that supports new treatments and cures, rural patients are likely to feel the consequences first."

More on rural MFN effects: https://t.co/z57R4qjsXA

[We Work for Health | WA @WWFH_WA]

"Europe and Japan once led the world in pharmaceutical innovation. That’s not the reality today, in large part because price controls reduced the incentive to invest in new treatments."

#MFN will put the U.S. at a competitive disadvantage: https://t.co/JqmMBlLKEK

[We Work for Health | WA @WWFH_WA]

"Policymakers are hyper-focused on individual components: drugs, managed care, PBMs, and hospitals, while interrogating each sector in separate hearings, as if healthcare weren’t deeply interrelated."

https://t.co/0fuA5nDFrl

[We Work for Health | WA @WWFH_WA]

"In plain terms, some of the nation’s largest, wealthiest hospitals are claiming the benefits of being both rural and urban even when the communities they serve don’t match that description."

#340B hospitals aren't serving patients as intended: https://t.co/5ThX4ToDdO

[We Work for Health | WA @WWFH_WA]

The best #healthcare decisions happen when the right people are in the room together.

WWFH is proud to sponsor the "Beyond the Bottom Line" forum on May 13: A full-day gathering of employers, health plans, providers, and community leaders.

Join us: https://t.co/9Ggl8qhkX7

[We Work for Health | WA @WWFH_WA]

"#MFN would tie what Americans pay for certain medicines to prices set by foreign governments. Those governments don’t just negotiate prices differently; they often decide which treatments patients can access using rigid formulas."

https://t.co/zxkZyUwpkS

[We Work for Health | WA @WWFH_WA]

Healthcare costs keep climbing. Quality gaps persist. Employers face mounting pressure to do more with less.

On May 13, WWFH is proud to sponsor Beyond the Bottom Line: Strategies for High-Value, Affordable Healthcare.

Register and learn more here: https://t.co/9Ggl8qhkX7